Radiotherapy after prostate cancer surgery lowers recurrence

Prostate cancer patients who receive radiotherapy within 6 months of surgery live longer than those who do not receive radiotherapy, according to an Italian study appearing in the Journal of Radiation Oncology, Biology, and Physics (2004; 59:674-83).

Related Videos

Expert discusses setting realistic expectations for Rezum for BPH

Considering Therapy De-Intensification: Balancing Adverse Effects and PSA Response

Nicolette G. Payne, MD, discusses risk factors for burnout among pediatric urologists

Sacral neuromodulation device empowers patients with greater UUI control

Howard Goldman, MD, on his experience with the Glean Urodynamics System

Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert Panel

Urology Crossroads: Looking Ahead in the Era of Immunotherapy for NMIBC

Study: Women with SCI are more likely to use indwelling catheters

Discover the Art and Science Behind Nerve Sparing Prostate Surgery

Ziho Lee, MD, previews 2025 Northwestern GU robotic reconstruction course

Related Content

Advertisement

July 21st 2025

Darolutamide plus ADT approved in EU for mHSPC

Hannah Clarke

This approval enables the use of darolutamide plus ADT with or without chemotherapy.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

July 18th 2025

Experts urge FDA to remove black box warning on low-dose vaginal estrogen

Hannah Clarke

In a panel meeting convened by the FDA, experts urged the agency to revise or remove the outdated boxed warning on hormone therapies for menopause.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 18th 2025

Urology in focus: Key moments from 2025

Hannah Clarke

Take a look back through some of the top stories from the first half of the year.

July 18th 2025

Enrollment goal met in trial of 64Cu-SAR-bisPSMA vs. 68Ga-PSMA-11 PET/CT

Hannah Clarke

The phase 2 Co-PSMA trial enrolled 50 patients with biochemical recurrence of prostate cancer.

Related Content

Advertisement

July 21st 2025

Darolutamide plus ADT approved in EU for mHSPC

Hannah Clarke

This approval enables the use of darolutamide plus ADT with or without chemotherapy.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

July 18th 2025

Experts urge FDA to remove black box warning on low-dose vaginal estrogen

Hannah Clarke

In a panel meeting convened by the FDA, experts urged the agency to revise or remove the outdated boxed warning on hormone therapies for menopause.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 18th 2025

Urology in focus: Key moments from 2025

Hannah Clarke

Take a look back through some of the top stories from the first half of the year.

July 18th 2025

Enrollment goal met in trial of 64Cu-SAR-bisPSMA vs. 68Ga-PSMA-11 PET/CT

Hannah Clarke

The phase 2 Co-PSMA trial enrolled 50 patients with biochemical recurrence of prostate cancer.